Clinical Trial Update: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on the safety and immunogenicity of a stabilized CH505 TF chTrimer vaccine in adults with HIV-1 on suppressive ART; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CH505 TF chTrimer vaccine (stabilized)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-1 | Phase 1 | Status: SUSPENDED